1st Annual Workshop on Non-Clinical Safety Assessment of Biopharmaceuticals

Wednesday 26 October 2011 – Janssen Pharmaceutica, Beerse, Belgium

Final programme

8:30 – 9:00 Coffee
9:00 – 9:05 Welcome M. Martens, President of Beltox

Morning session 1: Introductory lectures (chair: J. Baumeister - Ablynx & M. Cornet - UCB Pharma)
9:05 – 10:05 Safety assessment of biologics: specific requirements for vaccines and antibodies R. Foster, CiToxLAB, F
10:05 – 11:05 Safety assessment of biologics: regulatory perspectives J.W. van der Laan, RIVM, NL
11:05 – 11:25 Coffee break

Morning session 2: Non-clinical safety evaluation of vaccines (chair: L. Segal - GSK Biologicals)
11:25 – 12:05 Prophylactic vaccine toxicology case study S. Gould, Sanofi-Pasteur, F
12:05 – 12:45 Vaccine adjuvants safety evaluation N. Garçon, GSK Biologicals, B
12:45 – 13:45 Lunch and networking

Afternoon session: Non-clinical safety evaluation of antibodies and nanobodies (chair: G. Bailey & I. Smyej - Johnson & Johnson)
13:45 – 14:25 Challenges in developmental and reproductive toxicity testing of biopharmaceuticals G. Weinbauer, Covance, D
14:25 – 14:55 Choice of species for reproductive toxicity studies with biopharmaceuticals A. Cauvin, UCB Pharma, B
14:55 – 15:15 Coffee break
15:15 – 15:55 Immunogenicity testing in support of nonclinical studies of biotherapeutics: experiences and challenges M.P. Bouche, Ablynx, B
15:55 – 16:35 Safety assessment of monoclonal antibodies: Specific requirements for infectious diseases T. Kwaks, Crucell, NL
17:25 – 17:35 Concluding remarks M. Cornet, Beltox & chair of the Organising Committee
17:35 – 19:00 Reception and networking

Organising Committee: Judith Baumeister (Ablynx), Annick Cauvin (UCB Pharma), Miranda Cornet (UCB Pharma), Ilham Smyej (Johnson & Johnson), Lawrence Segal (GSK Biologicals) with the technical assistance of Marleen Harlam (Beltox) and Karin Van Tulden (Johnson & Johnson)

Info and registration: www.beltox.be